ViraCyte Granted U.S. FDA Fast Track Designation for Viralym-C

SAN FRANSICSCO, Jan. 10, 2017 -- (Healthcare Sales & Marketing Network) -- ViraCyte, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Viralym-C, ViraCyte's T cell immunotherapy product designed to... Biopharmaceuticals, FDA ViraCyte, Viralym-C, immunotherapy, cytomegalovirus

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2042044

Source: HSMN NewsFeed - January 10, 2017 Category: Pharmaceuticals Source Type: news

More News: Cytomegalovirus | Food and Drug Administration (FDA) | Immunotherapy | Marketing | Pharmaceuticals